FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chem...

por Larkins, Erin, Blumenthal, Gideon M., Yuan, Weishi, He, Kun, Sridhara, Rajeshwari, Subramaniam, Sriram, Zhao, Hong, Liu, Chao, Yu, Jingyu, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Publicado 2017

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

por Odogwu, Lauretta, Mathieu, Luckson, Blumenthal, Gideon, Larkins, Erin, Goldberg, Kirsten B., Griffin, Norma, Bijwaard, Karen, Lee, Eunice Y., Philip, Reena, Jiang, Xiaoping, Rodriguez, Lisa, McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Publicado 2018

US Food and Drug Administration regulatory updates in neuro-oncology

por Mehta, Gautam U., Barone, Amy K., Bradford, Diana, Larkins, Erin, Kim, Janice, Pai-Scherf, Lee, Jaigirdar, Adnan, Shah, Mirat, Wedam, Suparna, Amiri-Kordestani, Laleh, Theoret, Marc R., Pazdur, Richard, Beaver, Julia A., Singh, Harpreet
Publicado 2021

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

por Odogwu, Lauretta, Mathieu, Luckson, Goldberg, Kirsten B., Blumenthal, Gideon M., Larkins, Erin, Fiero, Mallorie H., Rodriguez, Lisa, Bijwaard, Karen, Lee, Eunice Y., Philip, Reena, Fan, Ingrid, Donoghue, Martha, Keegan, Patricia, McKee, Amy, Pazdur, Richard
Publicado 2017

Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data

por Liu, Qi, Zhang, Chenan, Huang, Yue, Huang, Ruihao, Huang, Shiew-Mei, Larkins, Erin, Stapleford, Liza, Rivera, Donna R., Kluetz, Paul G., Wang, Shenggang, Zhu, Hao, Weese, James, Cromartie, Elizabeth, Teka, Mahder, Walters, Sheetal, Wolf, Frank, Brown, Thomas D.
Publicado 2023